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 Gal-3 is a beta-galactoside–binding lectin
that regulates inflammation and fibrosis
and is highly predictive of heart failure
events and mortality.
 In a randomized placebo-controlled trial
of MCP, Gal-3 inhibition did not influence
collagen markers, echocardiographic
measures, or vascular function.
 Baseline Gal-3 levels were higher in
women compared with men.
 Consistent with previous studies, higher
Gal-3 levels were associated with dia-
betes and reduced GFR.https://doi.org/10.1016/j.jacbts.2020.10.006
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13SUMMARY
AB BAND ACRONYM S
AIx = augmentation index
AP = augmentation pressure
CITP = N-terminal telopeptide
of type I collagen
eGFR = estimated glomerular
filtration rate
Gal-3 = galectin-3
HF = heart failureWe investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen
metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3
levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced
glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change
collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further
investigation. (J Am Coll Cardiol Basic Trans Science 2021;6:12–21) © 2021 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).left ventricularLV =MCP = modified citrus pectin
MMP = matrix
metalloproteinase
PICP = C-terminal propeptide
of type I procollagen
PIIINP = N-terminal propeptide
of type III procollagen
PWV = pulsed wave velocityH eart failure (HF) is an important publichealth concern, with a lifetime risk of 1 in5 for both men and women at 40 years of
age (1). HF development is often a clinically incon-
spicuous process, characterized by progressive car-
diac remodeling that is not diagnosed until late in
the disease course. Accordingly, most available thera-
pies are implemented during the symptomatic phase
of HF when extensive remodeling has already
occurred with limited benefit, garnering considerable
interest in treatment strategies that target individuals
prior to the symptom onset. Indeed, in a prevention
trial of patients with asymptomatic left ventricular
(LV) dysfunction, treatment with enalapril was asso-
ciated with a reduction in mortality that was sus-
tained over 12 years (2,3).
Cardiac fibrosis, a pathologic phenomenon caused
by numerous conditions including hypertension,
ischemia, and aging, contributes to the pathophysi-
ology of HF (4). Galectin-3 (Gal-3) is a beta-galacto-
side–binding lectin that plays an important role in
regulating inflammation and fibrosis. Gal-3 is known
to be up-regulated in a number of human fibrotic
diseases, including liver cirrhosis (5), pulmonary
fibrosis (6), and most recently, cardiac fibrosis (7). We
and others have previously shown that elevated
circulating Gal-3 levels are associated with incident
HF events and mortality in the community (8,9). Most
recently, we found that longitudinal changes in Gal-3
were highly predictive of HF independent of baseline
Gal-3 levels (10). Among individuals with existing HF,
Gal-3 has been approved as a prognostic biomarker of
HF and the measurement of Gal-3, alone or in a
multimarker strategy, may provide additional risk
stratification (11).
Modified citrus pectin (MCP), a soluble dietary fiber
found in citrus fruit, is a direct Gal-3 inhibitor that
binds to the carbohydrate recognition domain of Gal-
3 (12,13). In an animal model of acute kidney injury,
MCP was shown to decrease Gal-3 expression and
renal fibrosis (14). Although MCP has been tested inhuman clinical trials of solid tumors and lead
intoxication (15–17), its role in attenuating
cardiovascular disease has not been previ-
ously investigated. In this context, we con-
ducted a randomized placebo-controlled trial
of MCP in patients with hypertension and
elevated Gal-3 levels to test our hypothesis
that direct inhibition of Gal-3 may reduce subclinical
cardiac fibrosis as assessed by biomarkers of collagen
metabolism, echocardiographic measures of diastolic
function, and vascular stiffness.
METHODS
STUDY SAMPLE. We included individuals 21 to 70
years of age with physician-diagnosed hypertension,
who were on stable therapy for at least 3 months, and
who had elevated Gal-3 levels. Elevated Gal-3 was
defined as $50th sex-specific percentile ($13.1 ng/ml
in men, $14.3 ng/ml in women) as derived from
normative values among participants of the Fra-
mingham Heart Study (9). Participants were screened
from October 2013 to March 2018. Of this screening
sample (n ¼ 275), we excluded participants with
nonelevated Gal-3 (n ¼ 186), with renal dysfunction
defined as estimated glomerular filtration rate
(eGFR) <45 ml/min/1.73 m2 (n ¼ 3), with aldosterone
antagonist use (n ¼ 1), with abnormal laboratory
values (i.e., hyperkalemia, anemia) (n ¼ 1), and who
withdrew participation after initial screening (n ¼ 16).
The remaining participants (n ¼ 68) were eligible for
randomization and subsequent follow-up as outlined
subsequently. The study was performed at the Mas-
sachusetts General Hospital and Boston University
Medical Center. All participants provided written
informed consent, and the study was approved by the
appropriate Institutional Review Boards.
STUDY PROCEDURES AND ASCERTAINMENT OF
OUTCOMES. We randomly assigned 68 participants
in double-blind fashion to receive either active MCP
or matching placebo at a dose of 4.8 g thrice daily for
FIGURE 1 CONSORT Diagram
Flowchart showing the number of patients who were screened, randomized into the treatment groups, completed the study, and included in
the final analysis. Gal-3 ¼ galectin-3; MCP ¼ modified citrus pectin.
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146 months in a 1:1 ratio (NCT03349775). MCP and
matching placebo were provided by EcoNugenics
(Pectasol-C, Santa Rosa, California) (Figure 1).
Randomization was done separately for men and
women and was performed in blocks of 4 to assure
balanced sex representation and group sizes. In-
vestigators and participants were blinded to
study assignment.
Clinical variables and collagen biomarkers. Medical his-
tory, physical examination, and fasting blood samples
were obtained at baseline examination prior to
randomization and again at final examination after
6 months of medication treatment. Blood serum was
separated, aliquoted, and stored at –80C for further
processing. Serum levels of C-terminal propeptide of
type I procollagen (PICP) (EIA MicroVue CICP, Quidel
Corporation, San Diego, California), N-terminal pro-
peptide of type III procollagen (PIIINP) (RIA, Orion
Diagnostica, Espoo, Finland), N-terminal telopeptide
of type I collagen (CITP) (RIA, Orion Diagnostica), and
matrix metalloproteinase (MMP)-1 (alphaLISA, Perki-
nElmer, Waltham, Massachusetts) were measured at a
core laboratory (18). Assay performance characteris-
tics are summarized in Supplemental Table 1.Measures of renal function (i.e., eGFR and urine
albumin-to-creatine ratio) were obtained from fasting
blood and urine samples at baseline and final
examinations.
Arter ia l tonometry methods . Supine measure-
ments of arterial stiffness were noninvasively
assessed using applanation tonometry or volumetric
displacement of the brachial artery using a cuff-based
system (SphygmoCor XCEL or SphygmoCor CvMS,
AtCor Medical, Naperville, Illinois) at baseline and
final examinations (19,20). Central aortic pressure
was derived using a generalized transfer function
applied to pressure tracings. Pulsed wave analysis
included ascertainment of augmentation pressure
(AP) (mm Hg) defined as the pressure the reflected
wave contributes to systolic blood pressure,
augmentation index (AIx) defined as ratio of AP to
pulse pressure, and AIx normalized to a heart rate of
75 beats/min. Carotid-femoral pulsed wave velocity
(PWV) (m/s) was obtained using electrocardiography-
gated pulse waveforms or cuff measurements (20).
Pressure tracing and waveform quality control
metrics were applied including pre-specified oper-
ator index or variability metrics. Intraobserver









Age, yrs 55  10 57  8 54  8
Male 112 (41) 11 (50) 14 (47)
Race
White 128 (48) 8 (36) 18 (60)
Black 108 (41) 13 (59) 11 (37)
BMI, kg/m2 31.0  14.0 30.0  5.9 33.5  6.5
Obesity 147 (53) 9 (41) 21 (70)
Systolic BP, mm Hg 128  14 126  12 129  10
Diastolic BP, mm Hg 80  9 78  11 81  9
Heart rate, beats/min 70  3 73  18 74  11
Hypertension treatment 373 (99) 22 (100) 30 (100)
Diabetes mellitus 65 (24) 5 (23) 12 (40)
Current smokers 21 (8) 6 (27) 0 (0)
Laboratory parameters
Galectin-3, mg/dl 12.7  4.3 17.9  3.5 17.5  4.1
eGFR, ml/min/1.73 m2 94.1  18.2 92.2  12.9 88.3  16.4
Creatinine, mg/dl 0.87  0.25 0.89  0.14 0.91  0.17
Hematocrit, % 41.3  3.4 42.5  3.5 41.9  3.4
Arterial tonometry parameters
AP, mm Hg 11.6  7.1 11.7  5.1 8.9  5.6
AIx, % 28.2  11.8 29.1  10.8 23.9  10.5
PWV, m/s 8.9  2.2 9.3  2.1 8.8  1.7
Values are mean  SD or n (%), unless otherwise noted.
AIx ¼ augmentation index; AP ¼ augmentation pressure; BMI ¼ body mass index; BP ¼ blood pressure;
eGFR ¼ estimated glomerular filtration rate; MCP ¼ modified citrus pectin; PWV ¼ pulsed wave velocity.
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15reproducibility measurements were performed on 16
randomly selected subjects, who underwent 2 sepa-
rate pulsed wave analysis measurements on the same
day. The intraclass correlation coefficient for reported
outcome variables was excellent and ranged between
93% and 94%.
Echocardiography. Participants underwent compre-
hensive transthoracic echocardiography including
2-dimensional pulsed wave and tissue Doppler
echocardiography using Vivid 7 and Vivid IQ ultra-
sonography systems (GE Healthcare, Milwaukee,
Wisconsin) at baseline and final examinations. Stan-
dard measurements included cardiac dimensions, LV
ejection fraction, fractional shortening, and diastolic
function assessment as previously described (21).
LV mass was calculated as follows: 0.8 (1.04 [LV
end-diastolic dimension þ LV posterior wall thickness
þ LV septal wall thickness]3  [LV end-diastolic
dimension3]) þ 0.6 (22). Speckle tracking–based ana-
lyses of LV global longitudinal strain were performed
offline with excellent reproducibility as previously
described (2D Cardiac Performance Analysis v1.1,
TomTec Imaging Systems; Unterschleißheim, Ger-
many) (23,24). Primary measures obtained included
global longitudinal strain of the apical 2- and 4-
chamber views. Echocardiography images were
analyzed by observers blinded to participant treat-
ment randomization, and measurements were made
in triplicate and averaged whenever possible. The
interobserver within-subject coefficients of variation
for longitudinal strain measures ranged from 3.0% to
4.0% (24).
STATISTICAL ANALYSIS. Baseline clinical character-
istics are presented by study group assignment
as mean  SD or percentages. Non-normally distrib-
uted variables including biomarkers were natural
log-transformed due to right-skewed distributions.
Galectin-3 values were standardized.
In cross-sectional analyses, we examined the as-
sociation of Gal-3 with clinical characteristics, arterial
stiffness, and renal function among all participants
who attended the screening visit (n ¼ 275). We
applied a log-normal generalized linear model for
continuous outcomes and a logistic model for
dichotomous outcomes. We adjusted for age, sex,
body mass index, diabetes mellitus, systolic blood
pressure, and eGFR for cross-sectional analyses and
further adjusted for heart rate in analyses of arterial
tonometry measures.
A total of 52 individuals had complete biomarker
data at baseline and 6-month follow-up and were
included in primary analyses. We examined changesin log-transformed collagen metabolism biomarkers
(PICP, PIIINP, CITP, MMP-1, and CITP:MMP-1 ratio)
between baseline and final examination in both MCP
and placebo treatment groups using paired Student’s
t-tests. The change from baseline was compared
between MCP and placebo groups using unpaired
Student’s t-tests. In secondary analyses, we used
paired Student’s t-tests to examine changes in Gal-3,
renal function, vascular stiffness, and echocardio-
graphic measures of strain, elastance, and diastolic
function in both treatment groups. Group differences
were also assessed using unpaired t tests.
For primary analyses comparing between-group
differences of collagen biomarkers between MCP
and placebo treatment groups, we used a Bonferroni-
corrected p value threshold of p ¼ 0.0125 (0.05/4
collagen biomarkers). All other analyses were
exploratory and considered statistically significant at
a 2-sided p value <0.05. Data analyses were
completed in SAS version 9.4 (SAS Institute, Cary,
North Carolina), R version 3.6.0 (R Foundation for
Statistical Computing, Vienna, Austria), and RStudio
version 1.2.5001 (RStudio, Boston, Massachusetts).
FIGURE 2 Cross-Sectional Correlation of Galectin-3 With eGFR
Line represents association between Gal-3 and eGFR by univariate linear regression:
eGFR ¼1.58xGal-3 þ114.08. eGFR ¼ estimated glomerular filtration rate.
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16RESULTS
A total of 275 participants attended the screening visit
(mean age 55  10 years, 59% women). In addition to
hypertension, cardiovascular comorbidities included
24% with diabetes, 53% with obesity (body mass
index $30 kg/m2), <1% with atrial fibrillation, and 8%
who were current smokers (Table 1 for clinical char-
acteristics). The average Gal-3 level was 13.0  4.7 ng/
ml in women and 12.2  3.6 ng/ml in men, with 31% of
both men and women meeting Gal-3 cutpoint criteria
for inclusion in the trial.
CLINICAL CORRELATES OF GAL-3 IN SCREENING
SAMPLE. In cross-sectional analyses (n ¼ 275), we
examined the association of Gal-3 with clinical char-
acteristics, renal function, arterial stiffness, echocar-
diographic parameters, and collagen markers
(Supplemental Tables 2 and 3). After multivariable
adjustment, clinical predictors of circulating Gal-3
levels included presence of diabetes and eGFR. Spe-
cifically, the presence of diabetes was associated with
a 0.45-SD higher Gal-3 level (b ¼ 0.45, SE ¼ 0.14;
p ¼ 0.001), and a 1-SD increase in eGFR was
associated with a 0.33-SD lower Gal-3 level (b ¼ –0.33,
SE ¼ 0.06; p ¼ 6.02 $ 10–7) (Supplemental Table 2
and Figure 2).When examining the association of Gal-3 levels
with arterial stiffness, echocardiographic parameters,
and collagen markers, we found no significant asso-
ciations (Supplemental Tables 2 and 3).
RANDOMIZED TRIAL OF GAL-3 INHIBITOR MCP
VERSUS PLACEBO. A total of 68 participants met
enrollment criteria and were randomized to the Gal-3
inhibitor MCP versus matching placebo treatment for
a total duration of 6 months. Of randomized partici-
pants, 52 completed the final study visit: 22 in the
MCP treatment group and 30 in the placebo group
(Figure 1). Treatment groups were similar in age and
sex (mean age 57  8 years, 50% women for the MCP
group; mean age 54  8 years, 53% women for the
placebo group), though the placebo group appeared
to be heavier (body mass index 33.5  6.5 kg/m2 for
the placebo group, 30.0  5.9 kg/m2 for the MCP
group). Most common side effects included diarrhea
(6 [27%] individuals in the MCP treatment group vs. 7
[23%] individuals in the placebo group), constipation
(3 [14%] individuals in the MCP treatment group vs. 8
[27%] individuals in the placebo group), and flatu-
lence (6 [27%] individuals in the MCP treatment
group vs. 6 [20%] individuals in the placebo group).
Less common side effects included nausea (1 indi-
vidual in the MCP treatment group) and asthma flare
(1 individual in the placebo group).
EFFECT OF GAL-3 INHIBITION ON COLLAGEN
MARKERS. In the primary trial analyses, levels of the
collagen metabolism marker PIIINP increased by 0.15
log-transformed units (p ¼ 0.02) after 6 months of
treatment with MCP compared with no significant
change in the placebo group (p ¼ 0.47) (Table 2,
Figure 3). There was a borderline statistically signifi-
cant between-group difference in the change in
PIIINP levels (p ¼ 0.05). There were no other differ-
ences comparing baseline with post-treatment
collagen biomarkers (PICP, CITP, and MMP-1) after
6 months of treatment regardless of treatment
assignment (Table 2).
EFFECT OF GAL-3 INHIBITION ON SECONDARY
ENDPOINTS. In secondary analyses, changes in Gal-
3, renal function, as quantified by eGFR, creatinine,
and urine albumin-to-creatine ratio, and vascular
stiffness, as quantified by AP, AIx, and PWV, did not
meet statistical significance in either treatment group
(Table 2). Although measures of vascular stiffness in
the MCP treatment group were lower at the end of the
trial compared with unchanged or worse measures in
the placebo arm, none of these differences were sta-
tistically significant. Echocardiographic parameters of
cardiac structure and function are summarized in
Table 2. LV mass index was lower after 6 months of
TABLE 2 Effect of Galectin-3 Inhibition on Clinical and Laboratory Parameters, Arterial Tonometry Measures, Collagen Markers, and
Echocardiographic Measures
Placebo MCP Between-Group Difference
Pre Post Difference Pre Post Difference p Value
Clinical parameters
Body mass index, kg/m2 33.5  6.5 33.6  6.6 0.13 30.0  5.9 30.3  5.5 0.06 0.88
Systolic BP, mm Hg 129  10 127  15 –1.50 126  12 128  15 1.83 0.50
Diastolic BP, mm Hg 81  9 78  9 –2.86 78  11 81  11 1.60 0.14
Heart rate, beats/min 74  11 76  12 1.21 73  18 74  11 2.70 0.74
Laboratory values
Galectin-3, mg/dl 17.6  4.1 17.1  10.3 –0.48 17.9  3.5 17.9  6.8 0.01 0.81
eGFR, ml/min/1.73 m2 89.2  16.0 89.4  15.1 0.29 91.7  13.0 89.9  14.6 –1.88 0.51
Creatinine, mg/dl 0.91  0.17 0.90  0.20 –0.01 0.89  0.14 0.90  0.10 0.02 0.61
UACR, mg/g 24.7  44.6 18.1  32.2 –7.84 17.7  26.0 19.8  32.7 –0.49 0.48
Arterial tonometry measures
AP, mm Hg 8.90  5.58 9.97  7.26 1.07 11.68  5.10 10.59  5.89 –1.09 0.13
AIx, % 23.86  10.50 23.27  14.78 –0.59 29.13  10.876 25.86  11.74 –3.27 0.36
PWV, m/s 8.83  1.71 8.82  2.18 –0.01 9.29  2.14 8.69  1.88 –0.54 0.32
Collagen markers*
PICP, ng/ml 4.37  0.39 4.30  0.30 –0.07 4.29  0.52 4.35  0.54 0.06 0.10
CITP, ng/ml 1.20  0.34 1.23  0.40 0.03 1.15  0.35 1.16  0.41 0.01 0.73
PIIINP, ng/ml 1.38  0.40 1.32  0.47 –0.06 1.40  0.37 1.53  0.33 0.15 0.054
MMP-1, ng/ml 2.09  0.72 2.03  0.81 –0.06 2.08  0.60 2.04  0.52 –0.04 0.76
CITP:MMP-1 ratio 0.36  0.82 0.46  0.88 –0.09 0.32  0.64 0.37  0.68 –0.05 0.70
Echocardiography measures
LV end-diastolic dimension, cm 4.66  0.44 4.62  0.48 –0.04 4.52  0.36 4.42  0.42 –0.10 0.57
LV wall thickness, cm 2.03  0.27 2.06  0.25 0.03 1.97  0.26 1.93  0.25 –0.04 0.23
LA diameter, cm 3.79  0.83 3.74  0.39 –0.05 3.50  0.49 3.62  0.33 0.12 0.12
LV mass index, g/m2 78.8  16.6 79.7  17.1 0.90 76.7  18.1 71.2  16.1 –5.47 0.08
Fractional shortening, % 42.50  7.50 41.50  6.17 –0.93 41.80  6.55 38.30  6.51 –3.50 0.26
DT, ms 215.1  34.6 223.4  37.6 8.27 207.9  29.1 229.3  32.4 21.38 0.28
E/A ratio 1.04  0.29 0.99  0.30 –0.05 1.20  0.68 0.97  0.27 –0.24 0.20
E/e’ ratio 8.95  3.54 8.86  2.77 –0.09 8.54  2.10 8.23  2.70 –0.31 0.74
EndoGLS, %† –17.50  3.20 –17.40  3.35 0.16 –18.50  5.65 –17.80  3.67 –0.80 0.23
Values are mean  SD. *Collagen markers are log-transformed. †Average of apical 2 and apical 4 global longitudinal strain.
A ¼ late mitral inflow velocity on Doppler; CITP ¼ C-terminal telopeptide of type I collagen; DT ¼ deceleration time; E ¼ early mitral inflow velocity on Doppler; E0 ¼ early
mitral annular velocity on tissue Doppler; EndoGLS ¼ endocardial global longitudinal strain; LV ¼ left ventricular; MMP ¼ matrix metalloproteinase; PICP ¼ C-terminal
propeptide of type I procollagen; PIIINP ¼ N-terminal propeptide of type III procollagen; UACR ¼ urine albumin-to-creatine ratio; other abbreviations as in Table 1.
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17MCP therapy (difference ¼ –5.47 g/m2, SE ¼ 2.19 g/m2;
p ¼ 0.02), with no change in the placebo group.
Similarly, mitral inflow deceleration time increased
by 21 ms (difference ¼ 21.38 ms, SE ¼ 8.71 ms;
p ¼ 0.02) in the MCP group without significant change
in the placebo group. Between-group differences,
however, were not significant. Other measures of
diastolic function, including mitral E/e0 ratio, as well
as cardiac mechanics as measured by global longitu-
dinal strain did not change in either treatment group.
DISCUSSION
We present the results of the first randomized trial of
MCP, a direct Gal-3 inhibitor, in human subjects with
hypertension and elevated Gal-3 levels for the pre-
vention of subclinical cardiac fibrosis. Our findingsare 3-fold. First, baseline Gal-3 levels were signifi-
cantly higher in women compared with men. Second,
in cross-sectional analyses, diabetes and reduced
eGFR were independent predictors of Gal-3 level.
Third, treatment with MCP compared with placebo
did not significantly influence collagen biomarker
levels, echocardiographic markers of diastolic func-
tion, or arterial stiffness. Taken together, our study
confirms previous associations of Gal-3 with diabetes
and eGFR but did not find attenuation of subclinical
measures of cardiovascular fibrosis with direct Gal-3
inhibition.
In our sample of 275 eligible participants, we
confirm previous observations, including signifi-
cantly higher baseline levels of Gal-3 in women
compared with men, and significant cross-sectional
association of Gal-3 with diabetes and an inverse
FIGURE 3 Change in Collagen Metabolism Biomarkers in Placebo Versus MCP Groups
Boxes show interquartile ranges and bars represent 25th and 75th percentile values. Dots represent outliers. Squares represent the means. *p < 0.05. CITP ¼ C-
terminal telopeptide of type I collagen; MCP ¼ modified citrus pectin; MMP ¼ matrix metalloproteinase; PIIINP ¼ N-terminal propeptide of type III procollagen;
PICP ¼ C-propeptide of type I procollagen.
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18association with eGFR. We previously showed that in
2,477 individuals in the community, women had
greater increases in Gal-3 over time compared with
men (10), and in a study of Gal-3 in 1650 participants
with symptomatic HF, female sex was independently
predictive of both baseline circulating Gal-3 levels
and change in Gal-3 levels at 4 months (25). Inter-
estingly, female sex was not independently associ-
ated with Gal-3 levels after multivariable adjustment
in our study, highlighting the potential role of
comorbidities, including diabetes and chronic kidney
disease, in modulating expression of Gal-3 in women
preferentially compared with men. Indeed, previous
studies have demonstrated that cardiovascular risk
factors, including age, diabetes, and body mass index
are all associated with both Gal-3 levels and rise in
Gal-3 over time in healthy individuals free of HF and
in individuals with symptomatic HF (9,25). Renal
dysfunction has been most strongly associated with
Gal-3 in epidemiologic studies of both healthy in-
dividuals and individuals with HF. In prior analyses
examining the association of Gal-3 with incident HF
events, adjustment for eGFR attenuated theassociation of Gal-3 with outcomes (9,10,25). We
again show a strong inverse relationship between Gal-
3 and eGFR, further validating the importance of Gal-
3 with kidney function and highlighting the need to
consider renal function when evaluating the associ-
ation of Gal-3 with HF risk.
Beyond clinical risk factors, we further examined
the associations of Gal-3 with vascular parameters,
echocardiographic measures, and collagen turnover
biomarkers but did not find meaningful associations
contrary to expectation. Two prior studies found
increased arterial stiffness, as measured by PWV,
with higher levels of Gal-3 (26,27), and a study of 115
patients presenting to the emergency department
with acute dyspnea found that higher Gal-3 levels
were significantly associated with echocardiographic
markers of LV filling and diastolic function, valvular
regurgitation, and right ventricular function (28). We
postulate that our neutral results may be related to
the restricted sample size or the nature of our study
sample, an ostensibly healthy sample with hyper-
tension that has not yet developed echocardiographic
evidence of remodeling.
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19In our primary analysis, we compared differences
in collagen turnover markers in 22 individuals ran-
domized to treatment with MCP and 30 randomized
to placebo. In contrast to our hypothesis that Gal-3
inhibition would reduce collagen turnover, we did
not find significant differences in collagen markers
between the active therapy and placebo arms. We
observed a borderline statistically significant
between-group difference in the change in PIIINP,
although this was driven primarily by an increase in
PIIINP in the MCP treatment group. Although we
did not find changes in markers of collagen meta-
bolism, it is worth describing the motivation for this
interventional trial. Circulating biomarkers of
collagen metabolism have been well correlated with
cardiac fibrosis in hypertensive heart disease and
HF (29,30). Prior studies have demonstrated a direct
correlation between circulating markers of collagen
turnover, histological myocardial fibrosis, and LV
chamber stiffness (31). Gal-3 is expressed in acti-
vated macrophages with binding sites localized to
the myocardial extracellular matrix and cardiac fi-
broblasts and is thought to promote collagen
deposition via activation of cardiac fibroblasts (7).
As such, Gal-3 has been previously correlated with
markers of collagen metabolism, specifically tissue
inhibitor of MMP-1, in healthy and hypertensive
subjects (32–35). Previous studies have found de-
creases in collagen markers with antihypertensive
therapy in patients with hypertension. Collectively,
these observations were the driving rationale for
this intervention study that interrogated the impact
of direct Gal-3 inhibition on circulating markers of
collagen metabolism, surrogate markers of cardiac
fibrosis. The one borderline finding of increased
PIIINP with MCP treatment is surprising. PIIINP, like
Gal-3, is a biomarker of cardiac fibrosis and has
been associated with HF prognosis. In a study of 63
patients with stable coronary artery disease,
elevated serum levels of Gal-3 were associated with
cardiac fibrosis assessed by late gadolinium
enhancement by cardiac magnetic resonance imag-
ing as well as impaired LV diastolic function,
whereas PIIINP was associated with diastolic
dysfunction but not late gadolinium enhancement,
suggesting that elevated levels of PIIINP may reflect
earlier stages of disease progression compared with
Gal-3 (36). Although our findings should not be
overinterpreted, it warrants further investigation
into the relationship between Gal-3 inhibition and
PIIINP. Finally, the present investigation sought to
modulate the Gal-3 pathway in individuals with
elevated Gal-3 levels but who had not yet devel-
oped irreversible cardiovascular remodeling orfibrosis. To that end, we enrolled individuals with
modest elevations in Gal-3 levels ($50th sex-
specific percentile) based on prior population data
(9). It is conceivable that treatment with MCP may
have demonstrated greater clinical benefit in in-
dividuals with higher baseline Gal-3 levels or more
advanced fibrosis.
Finally, we also report neutral results for our
exploratory analyses examining the effect of Gal-3
inhibition on vascular function and cardiac diastolic
function. Of interest, although the differences in
vascular stiffness were not statistically different be-
tween the MCP therapy and placebo arms, the abso-
lute reduction in vascular stiffness measures, in
particular AP and AIx, were greater in the MCP group.
Separately, there was a borderline but nonsignificant
difference in LV mass index between the MCP
and placebo groups. This result must be cautiously
interpreted given its lack of significance but does
argue for further exploration.
STUDY LIMITATIONS. First, there was significant
attrition bias, as premature discontinuation of the
study drug was significantly higher in the MCP arm
compared with placebo due to gastrointestinal side
effects. As such, adherence to treatment at 6 months
was 65% in the MCP arm compared with 88% in the
placebo group. Second, owing to significant attrition,
the sample size was inherently reduced, potentially
limiting power to detect meaningful differences be-
tween the MCP and placebo groups. Moreover, after
premature discontinuation of the study drug, base-
line characteristics were no longer balanced between
the intervention and placebo arms, potentially con-
founding interpretation of trial results. Last, owing to
variable gastrointestinal MCP absorption related to
oral administration, participants were instructed to
take MCP a half-hour before or 2 h after food for
optimal absorption.
CONCLUSIONS
In summary, we present the results of the first
proof-of-concept interventional trial of Gal-3 inhi-
bition for the attenuation of cardiac fibrosis in hu-
man subjects. We demonstrate higher baseline Gal-3
levels in women compared with men and further
validate previous associations of Gal-3 with clinical
risk factors including diabetes and reduced eGFR.
Gal-3 inhibition via MCP did not influence surrogate
measures of cardiac fibrosis, including collagen
turnover markers, echocardiographic measures, and
vascular function in human subjects at risk for HF.
Whether Gal-3 inhibition among individuals with
existing HF may meaningfully attenuate cardiac
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In the
first proof-of-concept interventional trial of Gal-3
inhibition in human subjects with hypertension, Gal-
3 inhibition with MCP did not influence collagen
markers, echocardiographic measures, or vascular
function. However, we showed that baseline Gal-3
levels were higher in women compared with men
and confirmed previous associations of Gal-3 with
diabetes and reduced eGFR.
TRANSLATIONAL OUTLOOK: Future studies are
needed to examine whether Gal-3 inhibition can
attenuate cardiac fibrosis and cardiovascular events in
individuals with HF.
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20fibrosis and, ultimately, clinical cardiovascular
events remains to be studied.
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